Huang De-Jia, Li Yan-Hao, Luo Yao-Chang, Huang Jun-Zhen, He Hai-Yuan
Department of Interventional Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China; Department of Interventional Radiology, The First Affiliated Hospital of Guangxi Traditional Chinese Medical University, Nanning, Guangxi 530021, P.R. China.
Department of Interventional Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Oncol Lett. 2016 Sep;12(3):2103-2106. doi: 10.3892/ol.2016.4846. Epub 2016 Jul 12.
Advanced hepatocellular carcinoma (HCC) with tumor thrombi invading the portal vein and extending into the right atrium (RA) through the hepatic vein is regarded as a terminal-stage condition. Intracardiac tumor thrombus and treatment via liver resection has been reported in the current literature, but results from this therapeutic approach remain unsatisfactory. The present study describes a rare case of HCC with metastatic portal vein, middle hepatic vein, inferior vena cava (IVC) and RA tumor thrombi, and pulmonary metastases. A 29-year-old woman was admitted to The First Affiliated Hospital of Guangxi Traditional Chinese Medical University (Nanning, China) subsequent to experiencing right upper quadrant abdominal pain. Following diagnosis, based on computed tomography analysis and laboratory data, the patient underwent an initial transcatheter arterial chemoembolization (TACE) treatment using fluorouracil (5-FU), pirarubicin, mitomycin C, Lipiodol and sodium alginate microball (KMG). At 1 month post-treatment, serum α-fetoprotein levels remained at >1,000 ng/ml. Subsequently, the patient underwent a second TACE treatment. At 1 month after the second treatment, the abdominal pain had been alleviated and the serum α-fetoprotein levels were reduced to <20 ng/ml. Imaging analysis indicated a marked reduction in tumor burden in the liver and the hepatic vein and IVC tumor thrombi. Furthermore, the portal vein and RA tumor thrombi, and the pulmonary metastases had disappeared. At 40 months after the second TACE therapy, the patient remains alive without any signs of recurrence. The present case demonstrates that the administration of TACE, using 5-FU, pirarubicin, mitomycin C, Lipiodol and KMG, functions as an effective treatment in cases of unresectable advanced HCC presenting with pulmonary metastases and extensive tumor thrombi in the IVC, the RA and one branch of the portal vein.
肿瘤血栓侵犯门静脉并经肝静脉延伸至右心房(RA)的晚期肝细胞癌(HCC)被视为终末期疾病。目前文献中已报道了心内肿瘤血栓及通过肝切除术进行治疗的情况,但这种治疗方法的效果仍不尽人意。本研究描述了1例伴有转移性门静脉、肝中静脉、下腔静脉(IVC)及RA肿瘤血栓和肺转移的罕见HCC病例。一名29岁女性因右上腹疼痛入住广西中医药大学第一附属医院(中国南宁)。经计算机断层扫描分析和实验室数据诊断后,患者首先接受了使用氟尿嘧啶(5-FU)、吡柔比星、丝裂霉素C、碘油和海藻酸钠微球(KMG)的经动脉化疗栓塞(TACE)治疗。治疗后1个月,血清甲胎蛋白水平仍>1000 ng/ml。随后,患者接受了第二次TACE治疗。第二次治疗后1个月,腹痛缓解,血清甲胎蛋白水平降至<20 ng/ml。影像学分析表明肝脏肿瘤负荷以及肝静脉和IVC肿瘤血栓明显减少。此外,门静脉和RA肿瘤血栓以及肺转移均消失。第二次TACE治疗后40个月,患者仍存活,无任何复发迹象。本病例表明,使用5-FU、吡柔比星、丝裂霉素C、碘油和KMG进行TACE治疗,对于出现肺转移以及IVC、RA和门静脉一个分支存在广泛肿瘤血栓的不可切除晚期HCC病例是一种有效的治疗方法。